How to buy Eli Lilly and Company shares

Own Eli Lilly and Company shares in just a few minutes.

Posted

Fact checked

Eli Lilly and Company is a drug manufacturers-general business based in the US. Eli Lilly and Company shares (LLY.US) are listed on the NYSE and all prices are listed in US Dollars. Eli Lilly and Company employs 35,065 staff and has a trailing 12-month revenue of around $23.2 billion.

How to buy shares in Eli Lilly and Company

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: LLY in this case.
  5. Research Eli Lilly and Company shares. The platform should provide the latest information available.
  6. Buy your Eli Lilly and Company shares. It's that simple.
The whole process can take as little as 15 minutes.

Eli Lilly and Company share price

Use our graph to track the performance of LLY stocks over time.

Eli Lilly and Company shares at a glance

Information last updated 2021-01-24.
Latest market close$N/A
52-week range$115.3609 - $206.54
50-day moving average $171.7124
200-day moving average $154.9002
Wall St. target price$195.41
PE ratio 33.7271
Dividend yield $3.4 (1.65%)
Earnings per share (TTM) $6.112
Promoted
eToro Free Stocks

Invest in Eli Lilly and Company shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Stake
£0
£0
Zero platform fee
Join and receive a free share worth up to £100
Access unlimited commission-free trading on 3,800+ US stocks and ETFs with Stake. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Moneyfarm helps you meet your investment goals with fully-managed portfolios designed around you. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Eli Lilly and Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Eli Lilly and Company under- or over-valued?

Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly and Company's P/E ratio

Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Eli Lilly and Company shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Eli Lilly and Company's PEG ratio

Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3601. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eli Lilly and Company's EBITDA

Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $7.7 billion.

The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.

Eli Lilly and Company financials

Revenue TTM $23.2 billion
Operating margin TTM 27.76%
Gross profit TTM $17.6 billion
Return on assets TTM 9.84%
Return on equity TTM 131.77%
Profit margin 24.01%
Book value $5.325
Market capitalisation $197.2 billion

TTM: trailing 12 months

How to short and sell Eli Lilly and Company shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "LLY.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 5.2 million Eli Lilly and Company shares held short by investors – that's known as Eli Lilly and Company's "short interest". This figure is 6.4% down from 5.6 million last month.

There are a few different ways that this level of interest in shorting Eli Lilly and Company shares can be evaluated.

Eli Lilly and Company's "short interest ratio" (SIR)

Eli Lilly and Company's "short interest ratio" (SIR) is the quantity of Eli Lilly and Company shares currently shorted divided by the average quantity of Eli Lilly and Company shares traded daily (recently around 3.8 million). Eli Lilly and Company's SIR currently stands at 1.37. In other words for every 100,000 Eli Lilly and Company shares traded daily on the market, roughly 1370 shares are currently held short.

However Eli Lilly and Company's short interest can also be evaluated against the total number of Eli Lilly and Company shares, or, against the total number of tradable Eli Lilly and Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eli Lilly and Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Eli Lilly and Company shares in existence, roughly 10 shares are currently held short) or 0.0066% of the tradable shares (for every 100,000 tradable Eli Lilly and Company shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eli Lilly and Company.

Find out more about how you can short Eli Lilly and Company stock.

Eli Lilly and Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Eli Lilly and Company's total ESG risk score

Total ESG risk: 32.36

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Eli Lilly and Company's environmental score

Environmental score: 0.63/100

Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Eli Lilly and Company's social score

Social score: 16.68/100

Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Eli Lilly and Company's governance score

Governance score: 13.31/100

Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Eli Lilly and Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Eli Lilly and Company was last rated for ESG on: 2019-01-01.

Total ESG score 32.36
Total ESG percentile 70.22
Environmental score 0.63
Environmental score percentile 1
Social score 16.68
Social score percentile 1
Governance score 13.31
Governance score percentile 1
Level of controversy 3

Eli Lilly and Company share dividends

44%

Dividend payout ratio: 44.43% of net profits

Recently Eli Lilly and Company has paid out, on average, around 44.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.65% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 1.65% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $3.4 per share.

While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.

Eli Lilly and Company's most recent dividend payout was on 10 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 February 2021 (the "ex-dividend date").

Have Eli Lilly and Company's shares ever split?

Eli Lilly and Company's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.

Eli Lilly and Company share price volatility

Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $115.3609 up to $206.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.3734. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Eli Lilly and Company overview

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Frequently asked questions

More guides on Finder

  • Invest in the London Stock Exchange

    Find out more about the London Stock Exchange, what companies are listed on it and how to invest in the largest exchange in Europe.

  • Invest in the Nikkei 225

    Find out more about the Nikkei 225, some companies that make it up and how you can invest in the Nikkei 225.

  • How to buy Eli Lilly and Company shares

    Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Charlie’s Holdings shares

    Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Lemonade shares

    Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Unity Software shares

    Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor

  • How to buy FuelCell Energy shares

    Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Eli Lilly and Company shares

    Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor

  • How to buy Zomedica Pharmaceuticals shares

    Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.

  • How to buy YRC Worldwide shares

    Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site